Kidney360 Publish Ahead of Print, published on April 22, 2021 as doi:10.34067/KID.0000732021 Sodium-Glucose Cotransporter 2 Inhibitors & Kidney Transplantation: What Are We Waiting For? Niralee Patel1 Judy Hindi2 Samira S Farouk2 1Division of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, 45267. 2Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Corresponding author: Samira S. Farouk, MD, MS Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, 10029 Email:
[email protected] Copyright 2021 by American Society of Nephrology. In recent robust randomized clinical trials (RCT), sodium-glucose cotransporter 2 (SGLT2) inhibitors, (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin), have been shown to dramatically decrease both kidney and cardiovascular (CV) adverse outcomes in patients with diabetic kidney disease (DKD), non- diabetic proteinuric kidney disease, and heart failure (HF) with reduced ejection fraction - with and without the presence of diabetes.1–6 For decades, both the nephrologist and transplant nephrologist’s arsenal for the management of proteinuric kidney disease has been limited to renin-angiotensin-aldosterone system blockade.7 Though SGLT2 inhibitors have taken the nephrology community by storm, patients with kidney transplants (KT) have been notably excluded from large RCT.8–10 Pathophysiologically, it seems likely they would also benefit from these apparent wonder drugs,